Navigation Links
Oncothyreon reports full year and fourth quarter 2007 financial results
Date:3/10/2008

---------- ---------- ---------- ----------

Revenue

Contract research and

development............ $ 29 $ 1,028 $ 631 $ 3,678

Contract manufacturing.. 1,617 - 2,536 -

Licensing revenue from

collaborative

agreements............. 212 43 528 182

Licensing, royalties

and other revenue...... 80 38 103 119

--------- ---------- ---------- ----------

1,938 1,109 3,798 3,979

--------- ---------- ---------- ----------

Expenses

Research and

development............ 2,278 2,885 10,011 12,200

Manufacturing........... 1,396 - 2,564 -

General and

administrative......... 3,567 2,298 11,797 7,636

Marketing and business

development............ 26 134 565 587

Depreciation............ 84 56 246 247

In-process research and

development............ - 24,920 - 24,920

Investment and other

loss (income).......... (22) (373) 371 (916)

Interest expense........ 3 2 5 10

Change in fair value of

warrant liability...... (242) (1,238) (1,421) (3,849)

--------- ---------- ---------- ----------

(7,090) (28,684) (24,138) (40,835)

--------- ---------- ---------- ----------

Loss before income taxes.. (5,152) (27,575) (20,340) (36,856)

Income tax recovery

Current...
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
2. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
3. Oncothyreon launches new corporate website
4. Oncothyreon to present at BIO CEO & Investor Conference
5. Oncothyreon highlights corporate and clinical objectives for 2008
6. Biomira announces plan to change name to Oncothyreon
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today ... Convention in Philadelphia, PA. , The presentation took place on Tuesday, June ... plans for the development of APX3330 for the treatment of pancreatic cancer. A ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students ... part in the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught ... summer 2014, this course combines students from both universities and is taught on ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... Genomatica , an emerging leader in sustainable chemicals, ... in the world, signed a broad memorandum of understanding (MOU) ... Study of a j oint venture for ...  Mitsubishi and Genomatica will explore forming a joint venture to ...
... April 28, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... DIFICID™ Phase 3 trials will be presented at the ... ILMay 7-10, 2011 Poster Presentation Information: Title: , Risk ... Clostridium difficile Infection: Patient Characteristics ...
... Calif., April 28, 2011 AquaStar Holdings, Inc. (Pink ... that the United States Patent and Trademark Office has ... Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay ... Capillary Sensor" details research completed at the State University ...
Cached Biology Technology:Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia 2Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia 3Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings 2Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings 3AquaStar Holdings, Inc.'s Client Receives U.S. Patent 7,708,944 for Portable Capillary Sensor Technology 2
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... backdrop of the Montreal Summit on global climate being ... monsoons, by a University of California, Santa Barbara scientist ... the journal Geology, underlines concern about the effects of ... vegetation have an important effect on African monsoon systems, ...
... south and central America such as the Amazon rainforest are ... around 65 species in Britain. UCL scientists have ruled out ... climate change, in a paper published on 7th December by ... , Instead, scientists believe that biology played a far ...
... uncovered new details about how estrogen can activate natural pathways ... raise the possibility that estrogen therapy may overcome resistance to ... December 7 issue of the Journal of the ... treatments such as chemotherapy or hormonal therapy fail to cause ...
Cached Biology News:Tropical Atlantic cooling and African deforestation correlate to drought, report scientists 2Why the Amazon rainforest is so rich in species 2Why the Amazon rainforest is so rich in species 3 Researchers uncover mechanisms of estrogen in promoting cell death in breast cancer 2
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
Biology Products: